SUPERNUS PHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $30.85 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-03
- SUPERNUS PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $30.83, a 43.66% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $21.46.
- SUPERNUS PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2013-06-30 was $0.66.
- SUPERNUS PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $24.37, a 51.18% increase from fiscal 2024.
- SUPERNUS PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $16.12, a 3.47% decline from fiscal 2023.
- SUPERNUS PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $16.70.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $30.85 10-Q · filed 2026-08-03 | |||
| 2026-03-31 | $30.83 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | $24.37 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $23.71 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $23.01 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | $21.46 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $16.12 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $20.23 10-Q · filed 2024-11-04 | |||
| 2023-12-31 | $16.70 10-K · filed 2025-02-25 | |||
| 2013-09-30 | $0.83 10-Q · filed 2013-11-13 | |||
| 2013-06-30 | $0.66 10-Q · filed 2013-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |